CLINICAL TRIALS PROFILE FOR VARICELLA VIRUS VACCINE LIVE
✉ Email this page to a colleague
All Clinical Trials for varicella virus vaccine live
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00641446 ↗ | Varicella Vaccination With Pulmicort | Completed | AstraZeneca | Phase 4 | 2001-10-01 | A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine |
| NCT01356004 ↗ | Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis | Completed | Cairo University | Phase 4 | 2010-01-01 | Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission. The investigators hypothesized that the combined use of live attenuated varicella vaccine as an adjuvant therapy to low dose cyclosporine in the treatment of severe resistant psoriasis can give positive responses. |
| NCT01474720 ↗ | Zostavax in Systemic Lupus Erythematosus | Completed | Oklahoma Medical Research Foundation | Phase 1 | 2011-11-01 | Individuals with systemic lupus erythematosus (SLE, lupus) appear to be at increased risk for the development of shingles, a painful reactivation of the varicella zoster virus that causes chicken pox. The investigators propose to study the immune response to commercially available Zostavax vaccine (shingles vaccine) in adult patients with SLE who have minimal disease activity and are on mild immunosuppressant medications, and to compare the immune response to that seen in healthy people following vaccination. Acceptable immunosuppressive drugs permitted in the study are those felt to be safe according to Centers for Disease Control guidelines. Ten healthy people and 10 SLE patients (all over 50 years of age) will be recruited to receive a single, standard dose of Zostavax. Blood samples and physical examination will be performed prior to injection, then 2,6,and 12 weeks following vaccination. All participants will receive active vaccine, there is no placebo group. |
| NCT01506661 ↗ | Safety of Zostavax Vaccination in Rheumatoid Arthritis | Completed | Oklahoma Medical Research Foundation | Phase 1 | 2012-01-01 | Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases. Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis. The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for varicella virus vaccine live
Condition Name
Clinical Trial Locations for varicella virus vaccine live
Trials by Country
Clinical Trial Progress for varicella virus vaccine live
Clinical Trial Phase
Clinical Trial Sponsors for varicella virus vaccine live
Sponsor Name
